Drug
rVA576
rVA576 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 50.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 2 completed trials
Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
2(50%)
Phase Distribution
Ph phase_2
1
25%
Ph phase_3
2
50%
Ph phase_1
1
25%
Phase Distribution
1
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
50.0%
2 of 4 finished
Non-Completion Rate
50.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Terminated(2)
Detailed Status
Terminated2
Completed2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 32 (50.0%)
Trials by Status
terminated250%
completed250%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects
NCT04035733
terminatedphase_3
rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study
NCT03829449
terminatedphase_1
Topical rVA576 for Treatment of Atopic Keratoconjunctivitis
NCT04037891
completedphase_3
Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576
NCT03588026
Clinical Trials (4)
Showing 4 of 4 trials
NCT04035733Phase 2
rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects
NCT03829449Phase 3
rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study
NCT04037891Phase 1
Topical rVA576 for Treatment of Atopic Keratoconjunctivitis
NCT03588026Phase 3
Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4